Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

13.18 +1.57 (+13.52%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Analysis: Viatris
In the past year, Viatris’s share price dropped by $2.76, or about 19%. 
Via Talk Markets
2 Superb Dividend Stocks to Buy Today and Hold Forever
These two companies have long runways for growth and decent yields today. 
Via The Motley Fool
3 Dividend Stocks That Are Ridiculously Cheap Right Now
Their valuations are low and their yields are high. 
Via The Motley Fool
Could This New Drug Launch Be a Hit for Viatris?
Viatris and Kindeva Drug Delivery could soon launch a generic version of AstraZeneca's Symbicort. 
Via The Motley Fool
Is Now the Time to Buy 3 of the S&P 500's Cheapest Stocks?
All of these stocks are trading at less than 7 times their future profits. 
Via The Motley Fool
Why These 7 Healthcare Stocks Could Soar in 2023
These healthcare stocks to buy are trading at a hefty discount and are poised to deliver robust returns in 2023. 
Via InvestorPlace
Golden Cross Appears Before Viatris Investors
Via Benzinga
What Does Viatris' Debt Look Like?
Over the past three months, shares of Viatris' Inc. (NASDAQ:VTRS) moved higher by 8.16%. Before having a look at the importance of debt, let's look at how much debt Viatris' has. 
Via Benzinga
Expert Ratings for Viatris
Within the last quarter, Viatris (NASDAQ:VTRS) has observed the following analyst ratings: 
Via Benzinga
Where Viatris Stands With Analysts
Viatris (NASDAQ:VTRS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Could This Drug News Give a Lift to Eli Lilly Stock?
In November, Eli Lilly received positive news from the U.S. Food and Drug Administration. 
Via The Motley Fool
1 Passive Income Stock to Buy While It's Cheap and 1 to Avoid
Both businesses are well-suited for producing passive income, but only one has the balance sheet and future prospects to make it work. 
Via The Motley Fool
3 High-Yielding Dividend Stocks That Could See Hikes in January
These stocks all pay more than 3% in dividends. 
Via The Motley Fool
'Sell The Darlings, Own The Dogs': Why It May Soon Be Time To Buy Tesla, Meta And Other Worst-Performing Stocks Of 2022
Several popular seasonal trading strategies are associated with the closing weeks and opening weeks of the calendar year. 
Via Benzinga
The 7 Best Crypto and Stocks to Buy as Christmas Gifts This Year
These stocks to buy as Christmas gifts provide a number of reasons for investors to rejoice this holiday season. 
Via InvestorPlace
4 Analysts Have This to Say About Viatris
Viatris (NASDAQ:VTRS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
2 Mammoth Stocks With Dividends to Buy Before 2022 Ends
Blue chip healthcare stocks Johnson & Johnson and Cigna are always in season. 
Via The Motley Fool
The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond
These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years. 
Via InvestorPlace
Want $3,000 in Dividend Income Next Year? Invest $50,000 in These 2 Stocks
These stocks have dividend yields exceeding 4%. 
Via The Motley Fool
Better Dividend Stock: AbbVie or Viatris?
These pharmaceutical companies are profitable and offer above-average dividends. 
Via The Motley Fool
3 Stocks With Dividends of 3% or More to Buy on the Dip
Three underpriced healthcare stocks provide an opportunity. 
Via The Motley Fool
Oyster Point Pharma Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From Oyster Point Pharma, Inc.
Via GlobeNewswire
Analyst Ratings for Viatris
Over the past 3 months, 4 analysts have published their opinion on Viatris (NASDAQ:VTRS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 10, 2022
Upgrades 
Via Benzinga
Want to Collect a High Dividend Every Month? Buy These 3 Stocks
Together, these stocks will ensure you're receiving a dividend each month of the year. 
Via The Motley Fool
Ocuphire Pharma Shares Jump After Global Licensing Pact For Nyxol Eye Drops
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Oyster Point Pharma, Inc. (Nasdaq - OYST), Benefitfocus, Inc. (Nasdaq - BNFT), Abiomed, Inc. (Nasdaq - ABMD), Atlas Corp. (NYSE - ATCO)
From Brodsky & Smith LLC
Via GlobeNewswire
Spirit AeroSystems, Oyster Point Pharma, Snap And Other Big Gainers From Monday
U.S. stocks closed higher on Monday, with the Dow Jones surging more than 400 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022
Upgrades 
Via Benzinga
Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday
Gainers 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.